Evaluation of Completeness of Suspected Adverse Drug Reaction Reports Submitted to the Mexican National Pharmacovigilance Centre

Drug Safety ◽  
2012 ◽  
Vol 35 (10) ◽  
pp. 837-844 ◽  
Author(s):  
Betsabé Sánchez-Sánchez ◽  
Marina Altagracia-Martínez ◽  
Jaime Kravzov-Jinich ◽  
Consuelo Moreno-Bonett ◽  
Everardo Vázquez-Moreno ◽  
...  

2015 ◽  
Vol 6 (4) ◽  
pp. 9-13 ◽  
Author(s):  
Nisha Jha ◽  
Devendra Singh Rathore ◽  
Pathiyil Ravi Shankar ◽  
Sudesh Gyawali ◽  
Mohamed Azmi Hassali ◽  
...  

Pharmacovigilance in Nepal is still in infancy. Till date only healthcare professionals are involved and the problem of underreporting is seen. The national pharmacovigilance centre is located in the national regulatory authority of Nepal, i.e. Department of Drug Administration (DDA). Lack of adequate human resources for managing the pharmacovigilance program in Nepal has been a limitation for the growth of pharmacovigilance activities. Currently, there is neither any involvement of community pharmacists in Adverse Drug Reaction (ADR) reporting process nor any involvement of consumers for the same. This paper reviews the current status of pharmacovigilance and mentions possible benefits of involving consumers or patients in the existing pharmacovigilance program. A systematic review were conducted by searching different databases like PubMed, Google scholar, EMBASE, NepJOL, and Scopus. This study also describes the role of healthcare professionals in ADR reporting, possible reasons for underreporting of ADRs, regulatory perspectives and benefits of involving consumers in pharmacovigilance. DOI: http://dx.doi.org/10.3126/ajms.v6i4.11659Asian Journal of Medical Sciences Vol.6(4) 2015 9-13



Drug Safety ◽  
2016 ◽  
Vol 39 (12) ◽  
pp. 1189-1195 ◽  
Author(s):  
Geneviève Durrieu ◽  
Julien Jacquot ◽  
Mathilde Mège ◽  
Emmanuelle Bondon-Guitton ◽  
Vanessa Rousseau ◽  
...  


2018 ◽  
Vol 17 (4) ◽  
pp. 339-345 ◽  
Author(s):  
Daniel Caldeira ◽  
Raquel Rodrigues ◽  
Daisy Abreu ◽  
Ana Marta Anes ◽  
Mário M. Rosa ◽  
...  


2018 ◽  
Vol 18 (1) ◽  
pp. 51-58 ◽  
Author(s):  
Rui Niu ◽  
Yufang Xiang ◽  
Tingting Wu ◽  
Zhi Zhang ◽  
Yue Chen ◽  
...  


2016 ◽  
Vol 50 (0) ◽  
Author(s):  
Inês Ribeiro-Vaz ◽  
Cristina Costa Santos ◽  
Ricardo Cruz-Correia

ABSTRACT OBJECTIVE To describe different approaches to promote adverse drug reaction reporting among health care professionals, determining their cost-effectiveness. METHODS We analyzed and compared several approaches taken by the Northern Pharmacovigilance Centre (Portugal) to promote adverse drug reaction reporting. Approaches were compared regarding the number and relevance of adverse drug reaction reports obtained and costs involved. Costs by report were estimated by adding the initial costs and the running costs of each intervention. These costs were divided by the number of reports obtained with each intervention, to assess its cost-effectiveness. RESULTS All the approaches seem to have increased the number of adverse drug reaction reports. We noted the biggest increase with protocols (321 reports, costing 1.96 € each), followed by first educational approach (265 reports, 20.31 €/report) and by the hyperlink approach (136 reports, 15.59 €/report). Regarding the severity of adverse drug reactions, protocols were the most efficient approach, costing 2.29 €/report, followed by hyperlinks (30.28 €/report, having no running costs). Concerning unexpected adverse drug reactions, the best result was obtained with protocols (5.12 €/report), followed by first educational approach (38.79 €/report). CONCLUSIONS We recommend implementing protocols in other pharmacovigilance centers. They seem to be the most efficient intervention, allowing receiving adverse drug reactions reports at lower costs. The increase applied not only to the total number of reports, but also to the severity, unexpectedness and high degree of causality attributed to the adverse drug reactions. Still, hyperlinks have the advantage of not involving running costs, showing the second best performance in cost per adverse drug reactions report.



2016 ◽  
Vol 44 (12) ◽  
pp. 304-304
Author(s):  
Jaclyn LeBlanc ◽  
Pamela Smithburger ◽  
Shawn Kram ◽  
Sandra Kane-Gill


PLoS ONE ◽  
2012 ◽  
Vol 7 (10) ◽  
pp. e46022 ◽  
Author(s):  
Janine Arnott ◽  
Hannah Hesselgreaves ◽  
Anthony J. Nunn ◽  
Matthew Peak ◽  
Munir Pirmohamed ◽  
...  




Sign in / Sign up

Export Citation Format

Share Document